Literature DB >> 15655260

Embryonic and adult stem cells as a source for cell therapy in Parkinson's disease.

Yossef S Levy1, Merav Stroomza, Eldad Melamed, Daniel Offen.   

Abstract

The rationale behind the use of cells as therapeutic modalities for neurodegenerative diseases in general, and in Parkinson's disease (PD) in particular, is that they will improve patient's functioning by replacing the damaged cell population. It is reasoned that these cells will survive, grow neurites, establish functional synapses, integrate best and durably with the host tissue mainly in the striatum, renew the impaired wiring, and lead to meaningful clinical improvement. To increase the generation of dopamine, researchers have already transplanted non-neuronal cells, without any genetic manipulation or after introduction of genes such as tyrosine hydroxylase, in animal models of PD. Because these cells were not of neuronal origin, they developed without control, did not integrate well into the brain parenchyma, and their survival rates were low. Clinical experiments using cell transplantation as a therapy for PD have been conducted since the 1980s. Most of these experiments used fetal dopaminergic cells originating in the ventral mesencephalic tissue obtained from fetuses. Although it was shown that the transplanted cells survived and some patients benefited from this treatment, others suffered from severe dyskinesia, probably caused by the graft's excessive and uncontrolled production and release of dopamine. It is now recognized that cell-replacement strategy will be effective in PD only if the transplanted cells have the same abilities, such as dopamine synthesis and control release, reuptake, and metabolizing dopamine, as the original dopaminergic neurons. Recent studies on embryonic and adult stem cells have demonstrated that cells are able to both self-renew and produce differentiated tissues, including dopaminergic neurons. These new methods offer real hope for tissue replacement in a wide range of diseases, especially PD. In this review we summarize the evidence of dopaminergic neuron generation from embryonic and adult stem cells, and discuss their application for cell therapy in PD.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15655260     DOI: 10.1385/JMN:24:3:353

Source DB:  PubMed          Journal:  J Mol Neurosci        ISSN: 0895-8696            Impact factor:   3.444


  156 in total

1.  Stem cells: Fusion brings down barriers.

Authors:  Alexander Medvinsky; Austin Smith
Journal:  Nature       Date:  2003-04-24       Impact factor: 49.962

2.  Stem cells. Plasticity: time for a reappraisal?

Authors:  Constance Holden; Gretchen Vogel
Journal:  Science       Date:  2002-06-21       Impact factor: 47.728

Review 3.  Nuclear transplantation, embryonic stem cells, and the potential for cell therapy.

Authors:  Konrad Hochedlinger; Rudolf Jaenisch
Journal:  N Engl J Med       Date:  2003-07-17       Impact factor: 91.245

4.  Fusion of bone-marrow-derived cells with Purkinje neurons, cardiomyocytes and hepatocytes.

Authors:  Manuel Alvarez-Dolado; Ricardo Pardal; Jose M Garcia-Verdugo; John R Fike; Hyun O Lee; Klaus Pfeffer; Carlos Lois; Sean J Morrison; Arturo Alvarez-Buylla
Journal:  Nature       Date:  2003-10-12       Impact factor: 49.962

5.  Treatment of traumatic brain injury in female rats with intravenous administration of bone marrow stromal cells.

Authors:  A Mahmood; D Lu; L Wang; Y Li; M Lu; M Chopp
Journal:  Neurosurgery       Date:  2001-11       Impact factor: 4.654

6.  Reconstruction of the nigrostriatal dopamine pathway by intracerebral nigral transplants.

Authors:  A Björklund; U Stenevi
Journal:  Brain Res       Date:  1979-11-30       Impact factor: 3.252

7.  Lithium chloride induces the expression of tyrosine hydroxylase in hNT neurons.

Authors:  T Zigova; A E Willing; E M Tedesco; C V Borlongan; S Saporta; G L Snable; P R Sanberg
Journal:  Exp Neurol       Date:  1999-06       Impact factor: 5.330

8.  Intraarterial administration of marrow stromal cells in a rat model of traumatic brain injury.

Authors:  D Lu; Y Li; L Wang; J Chen; A Mahmood; M Chopp
Journal:  J Neurotrauma       Date:  2001-08       Impact factor: 5.269

9.  Blastula-stage stem cells can differentiate into dopaminergic and serotonergic neurons after transplantation.

Authors:  T Deacon; J Dinsmore; L C Costantini; J Ratliff; O Isacson
Journal:  Exp Neurol       Date:  1998-01       Impact factor: 5.330

10.  Neuroprotection through delivery of glial cell line-derived neurotrophic factor by neural stem cells in a mouse model of Parkinson's disease.

Authors:  P Akerud; J M Canals; E Y Snyder; E Arenas
Journal:  J Neurosci       Date:  2001-10-15       Impact factor: 6.167

View more
  5 in total

Review 1.  Regeneration of intervertebral disc by mesenchymal stem cells: potentials, limitations, and future direction.

Authors:  Victor Y L Leung; Danny Chan; Kenneth M C Cheung
Journal:  Eur Spine J       Date:  2006-07-15       Impact factor: 3.134

2.  Olfactory cells via nasal biopsy reflect the developing brain in gene expression profiles: utility and limitation of the surrogate tissues in research for brain disorders.

Authors:  Yasue Horiuchi; Shin-Ichi Kano; Koko Ishizuka; Nicola G Cascella; Seiji Ishii; C Conover Talbot; Andrew E Jaffe; Hideyuki Okano; Jonathan Pevsner; Carlo Colantuoni; Akira Sawa
Journal:  Neurosci Res       Date:  2013-10-11       Impact factor: 3.304

3.  Induction of adult human bone marrow mesenchymal stromal cells into functional astrocyte-like cells: potential for restorative treatment in Parkinson's disease.

Authors:  Merav Bahat-Stroomza; Yael Barhum; Yossef S Levy; Olga Karpov; Shlomo Bulvik; Eldad Melamed; Daniel Offen
Journal:  J Mol Neurosci       Date:  2009-01-06       Impact factor: 3.444

4.  Stem cells in drug screening for neurodegenerative disease.

Authors:  Hyun-Jung Kim; Chang Yun Jin
Journal:  Korean J Physiol Pharmacol       Date:  2012-02-28       Impact factor: 2.016

Review 5.  Trends in the molecular pathogenesis and clinical therapeutics of common neurodegenerative disorders.

Authors:  Yahya E Choonara; Viness Pillay; Lisa C Du Toit; Girish Modi; Dinesh Naidoo; Valence M K Ndesendo; Sibongile R Sibambo
Journal:  Int J Mol Sci       Date:  2009-06-03       Impact factor: 6.208

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.